New Pill Doubles Survival Time for Advanced Pancreatic Cancer Patients
Daraxonrasib extended median survival to 13.2 months vs 6.7 months on chemo in a Phase 3 trial — a potential landmark for one of cancer's deadliest diagnoses.
Summary
A new daily pill called daraxonrasib showed remarkable results in a Phase 3 clinical trial for advanced pancreatic cancer. Patients taking the drug lived a median of 13.2 months, nearly double the 6.7 months seen in patients receiving standard chemotherapy. Developed by Revolution Medicines, the drug targets a notoriously difficult cancer with historically grim survival rates. The company plans to seek FDA approval based on this data, and experts suggest approval could come quickly. Paul Oberstein of NYU Langone's Perlmutter Cancer Center, a trial investigator, described the results as potentially opening a new era of pancreatic cancer treatment. This is a significant development for patients and clinicians facing one of oncology's most stubborn challenges.
Detailed Summary
Pancreatic cancer is one of the most lethal malignancies known, with five-year survival rates in advanced stages typically below 5%. Standard chemotherapy has offered limited benefit for decades, making any meaningful survival improvement a major clinical event. This week, Revolution Medicines announced Phase 3 trial results that experts are calling a potential turning point.
The trial compared daraxonrasib — a once-daily oral pill — against standard chemotherapy in patients with advanced pancreatic adenocarcinoma. Patients on daraxonrasib lived a median of 13.2 months, compared to just 6.7 months for those on chemotherapy. That near-doubling of median survival in a disease this aggressive is being described by trial investigators as potentially historic.
Paul Oberstein, a pancreatic cancer specialist at NYU Langone's Perlmutter Cancer Center and a trial investigator, spoke with STAT News about the significance of the findings. He suggested the results could 'open up a new era' of treatment for a disease that has resisted therapeutic progress for generations. Revolution Medicines has announced plans to submit the data to the FDA for approval, with observers noting the strength of the data could accelerate the review timeline.
For health-conscious individuals and those with family histories of pancreatic cancer, this development signals that targeted molecular therapies are beginning to crack one of oncology's hardest problems. Daraxonrasib appears to represent a new class of RAS-targeting agents, a pathway long considered 'undruggable' that is now yielding to next-generation inhibitor design.
Important caveats remain. The full article is behind a paywall, limiting access to complete trial details including side effect profiles, patient selection criteria, and subgroup analyses. FDA approval has not yet been granted, and real-world outcomes may differ from controlled trial conditions. Nonetheless, this represents one of the most promising signals in pancreatic oncology in recent memory.
Key Findings
- Daraxonrasib nearly doubled median survival vs chemotherapy: 13.2 months vs 6.7 months in Phase 3.
- The drug is a daily oral pill, offering a more convenient format than IV chemotherapy regimens.
- Revolution Medicines plans to file for FDA approval; fast-track designation is considered likely.
- Trial investigator calls results a potential 'new era' for one of oncology's deadliest cancers.
- Daraxonrasib likely targets the RAS pathway, long considered undruggable in cancer therapy.
Methodology
This is a news report from STAT News, a credible specialized health and biotech journalism outlet. The article is based on Phase 3 clinical trial data announced by Revolution Medicines and includes expert commentary from a trial investigator. Full trial methodology is behind a paywall and has not yet been published in a peer-reviewed journal.
Study Limitations
The full article is paywalled, restricting access to complete trial data including adverse events, patient demographics, and subgroup outcomes. FDA approval has not been granted and the submission timeline was not specified. Results are from a company announcement and have not yet been independently peer-reviewed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.